This is a randomised, double-blind, placebo-controlled, parallel group, multi-center, multi-national, Phase II/III study to assess the efficacy and safety of three different doses regimens of Oralgen Grass Pollen in patients with grass pollen-related allergic rhinoconjnctivitis.